WO2007028823A1 - Pcv-2 vaccine - Google Patents
Pcv-2 vaccine Download PDFInfo
- Publication number
- WO2007028823A1 WO2007028823A1 PCT/EP2006/066161 EP2006066161W WO2007028823A1 WO 2007028823 A1 WO2007028823 A1 WO 2007028823A1 EP 2006066161 W EP2006066161 W EP 2006066161W WO 2007028823 A1 WO2007028823 A1 WO 2007028823A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pcv
- vaccine
- orf
- piglets
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a vaccine against porcine drcovirus (PCV-2) and a method for the manufacture of such a vaccine, for protecting piglets against PCV infection.
- PCV-2 porcine drcovirus
- PCV-2 is thought to be linked to the post-weaning multisystemic wasting syndrome (PMWS) observed in young pigs.
- PMWS post-weaning multisystemic wasting syndrome
- PCV-1 PCV-1
- PCV1 and PCV-2 are small (17 nm) icosahedral non-enveloped viruses containing a circular single stranded DNA genome.
- the length of the PCV-2 genome is about 1768 bp.
- ORF-2 of PCV encodes the putative capsid protein of the virus.
- the ORF 2 of PCV 2 encodes a protein of 233 amino acids.
- the ORF 2 of all PCV-2 isolates share 91- 100% nucleotide sequence identity and 90-100% deduced amino acid sequence identity.
- PDNS diporcine dermatitis and nephropathy syndrome
- PCV-2 proteins have already been expressed in various expression systems. For example, Liu et al. (Protein Expression and Purification, 21 , 115-120 (2001 ) expressed a fusion protein of the entire protein encoded by ORF-2 of PCV-2 linked to a MBP His tag, in E.coli. Kim et al.
- the piglets need to obtain their priming vaccination already in the first week(s) of age so they can receive the booster vaccination round the time of weaning and have obtained full protection against PCV-2 infection just after weaning.
- Piglets are likely to have maternally derived antibodies (MDA) against PCV-2.
- MDA maternally derived antibodies
- a distribution of MDA titers in piglets used in experiments with a vaccine according to the invention is given in the Examples). It is however, well known that the presence of maternally derived antibodies will interfere with vaccination. Piglets may have different titers of MDA. Very high passive MDA titers may protect the piglets against PCV-2 infection (Merial: 'PCV-2 Diseases: From research back to the field strain", 18 th IPVS, Hamburg Germany, June 2004, page 99-101 ).
- piglets with lower MDA titers will not be protected against PCV-2 infection when they have reached the relevant age (i.e. post weaning).
- the MDA titer may be too low to provide protection against PCV-2 infection, while still high enough to interfere with vaccination with, for example, a conventional inactivated PCV-2 vaccine.
- an inactivated vaccine may contain less antigen due to the fact that the virus can not be propagated to high titers in cell culture (or complicated and time consuming concentration procedures should be introduced in vaccine production).
- a vaccine according to the invention has been found to provide adequate protection against PCV-2 infection.
- a vaccine has been provided that can be used in a method to protect piglets, even piglets which are MDA positive against PCV-2, against infection with PCV-2, and thus against PCV-2 related diseases, most notably PMWS and PDNS.
- the present invention provides a vaccine against PCV-2 comprising at least 20 microgram/dose of ORF-2 protein of porcine drcovirus type 2 (PCV-2). It has been found that a vaccine containing at least 20 microgram (ug) of ORF-2 protein of PCV-2 per dose is capable of eliciting a protective immune response against PCV-2 infection (and thus against PCV-2 related diseases like PMWS and PDNS) even in the face of MDA.
- the vaccine contains at least 50 ug per dose, and most preferably 80 ug per dose.
- Vaccines according to the present invention with an antigenic mass up to 275 ug per dose could even be prepared, and such vaccines still did not elicit local reactions at the injection site.
- even more micrograms of antigen can be put in a vaccine dose of a vaccine according to the invention, but if the protection obtained with the vaccine is not improved with a higher dose the increase in antigenic load only results in the vaccine being more expensive than necessary.
- an increasing dose of antigen may eventually lead to unacceptable local reactions at the injection site, which should be avoided.
- a method to measure the antigenic mass is given in the experimental part of this application.
- a vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.
- suitable expression systems known in the art may be used as well in a method to prepare a vaccine according to the invention, it has been found that the use of the baculo expression system results in the production of high yields of viral antigen, which moreover show a good antigenicity. The use of the baculo expression system thus eliminates the need for complicated and time consuming procedures to concentrate the antigen to a suitable level when it cannot be produced at a high concentration, for example in a virus infected cell culture.
- the most commonly used baculo expression vector is Autographa californica often used with an insect cell culture of SF-9, SF-21 or High five insect cells.
- SF-9 and SF-21 are ovarian cell lines from Spodoptera frugiperda, High five cells are derived from egg cells from Trichoplusia ni.
- the PCV-ORF-2 gene should be placed under the control of a suitable promoter.
- Most commonly used promoters in the baculovirus expression system are the promoters for the polyhedrin gene and the promoter for the p10 gene, meaning that the ORF-2 PCV-2 gene sequence is inserted in an insertion site in either the polyhedron locus or the p10 locus in the baculovirus genome.
- baculovirus expression system is given in "Baculovirus Expression vectors" by D. R. O'Reilly, L. K. Miller, and V.A. Luckow (1992, W. H. Freeman & Co, New York). Furthermore baculovirus derived expression vectors and complete expression systems are commercially available from many different companies.
- a vaccine according to the invention may further comprise a suitable adjuvant.
- suitable adjuvant systems are known in the art, for example commonly used oil in water adjuvant systems. Any suitable oil may be used, for example a mineral oil known in the art for use in adjuvantia.
- the oil phase may also contain a suitable mixture of different oils, either mineral or non-mineral. Suitable adjuvantia may also comprise vitamin E, optionally mixed with one or more oils.
- the water phase of an oil in water adjuvanted vaccine will contain the antigenic material. Suitable formulations will usually comprise from about 25-60% oil phase (40-75% water phase).
- suitable formulations may comprise 30% water phase and 70% oil phase or 50% of each.
- a vaccine according to the invention may be administered via any suitable route known in the art such as intramuscularly, intradermally or subcutaneously, whereby intramuscular administration is preferred.
- the present invention further provides a method for the manufacture of a vaccine intended for the protection of young piglets, which are PCV-2 MDA positive, against PCV-2 infection, wherein said vaccine is provided with at least 20 ug/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2).
- a vaccine (prepared by a method) according to the invention can be used in a method to protect young piglets against PCV-2 infection.
- a vaccine according to the invention can even be used in a method for the protection of young piglets, which are positive for maternally derived antibodies (MDA) against PCV-2, against infection with PCV-2.
- MDA maternally derived antibodies
- a vaccine according to the invention can protect piglets, even when they have a relatively high titer of MDA against PCV-2.
- a distribution of MDA titers in young piglets encountered in the field at various farms across Europe are reflected in table 1 , and the protection provided by a vaccine according to the invention is reflected in table 2.
- a vaccine according to the invention can even provide adequate protection against PCV-2 infection to piglets that have MDA titers falling in "cluster 2" as defined in the Examples (Table 2). Piglets falling in this cluster have MDA titers between 8 and 12 Iog2 which is a high MDA titer.
- a vaccine according to the invention can therefore even be used in a method for the protection of young piglets, which have an MDA titer against PCV-2 up to 10 Iog2, or even 12log2 (as measured with a method as indicated in the Examples). From Table 1 it can be seen that about 55% of the piglets collected at various farms over Europe fall within this cluster 2 (while of course piglets falling within cluster 1 , which have a lower MDA titer and which comprise 32% of the population, are also protected by a vaccine according to the invention). Thus it can be concluded that a vaccine according to the invention provides protection to the vast majority of piglets encountered in the field, including those with high MDA titers.
- the vaccine is preferably administered in a 2 shot vaccination regimen, whereby the first shot (priming vaccination) is given to the piglets in the first to fourth week of age, preferably prior to weaning, for example in the first week of age.
- the second shot (boosting vaccination) can be given about 3 weeks later. In this way the piglets will have obtained full protection against PCV-2 infection just after weaning which is when the piglets are most susceptible to PCV-2 infection and thus become susceptible to PMWS and PDNS.
- Example 1 (Determination of maternally derived) PCV-2 specific antibody titers.
- Antibody titers against PCV-2 can be determined in the following manner: A monolayer of PK15 cells was formed in 96-well tissue culture plate. At 80% confluency the cells were infected with a field isolate of PCV-2 and further incubated for 2 days at 37°Cin a CO 2 incubator. After this period the cells were fixed in Ethanol and stored at 2-8°C until use. Plates are used for tests when approximately 20% of the cells were infected.
- PCV-2 specific antibody titre of a given serum serial dilutions are made and incubated on the ethanol fixated cells. After 1 hour of incubation at 37 0 C the plates are washed with tap water and the bound antibodies detected by incubation with FITC-labeled Rabbit anti-Swine IgG . The titre of a given serum is expressed as the reciprocal of the highest dilution where a PCV-2 specific antibody response can still be observed.
- Sera were collected from 232 piglets from various countries across Europe.
- Table 1 The distribution of maternally derived antibody titres in a group of 232 young piglets
- cluster 1 three clusters can be distinguished: Cluster 1 ; piglets with titres smaller than 8, cluster 2; piglets with titres from 8 to 12 and cluster 3; piglets with titres of 13 and higher.
- cluster 3 the maternally derived antibody titres are that high that it is expected that the piglets will be protected during the critical period of age (Merial: 'PCV-2 Diseases: From research back to the field strain", 18 th IPVS, Hamburg Germany, June 2004, page 99-101 ).
- cluster 1 the maternally derived antibody titres are that low that most of these piglets can be easily vaccinated.
- cluster 2 the antibody titres are of such a magnitude that a conventional vaccination approach will probably fail to immunize the majority of this group. Since more than halve of the piglets seem to fall into this cluster it will be of the uttermost importance to be able to protect the piglets in this cluster if one wants to eliminate PMWS from a farm.
- PCV-2 virus was isolated from lung tissue of a feeder pig showing clinical and histopathological signs of PMWS using PCV-free Swine Testis (ST) cells. The virus was propagated through five passages on PCV-free PK15 cells.
- DNA was isolated from a preparation of PCV-2 virus purified from infected PK15 cell supernatant. PCR was done to amplify the ORF-2 gene based on published sequences, using primers containing BamW restriction sites (forward primer: CGG GAT CCG TTT TCA GCT
- the resulting amplicon encompasses the complete ORF-2 gene plus flanking BamH1 restriction sites.
- This plasmid contains the p10 promotor upstream of the insertion site, allowing for expression of foreign genes under control of the p10 promotor.
- TOP 10F' bacteria (Invitrogen, Carlsbad, USA) were transformed with the ligation mixture, and clones which contained the correct construct were selected based on their sequence.
- a positive clone was expanded and the transfer plasmid DNA was again retested using sequencing.
- Sf9 Spodoptera frugiperda
- transfer plasmid and Bsu3S ⁇ - digested ⁇ cNPV baculovirus DNA using CellFectine (Life Technologies, Gaithersburg, USA).
- the supernatant of the transfection was harvested at 3 days post transfection and plaque purifications were performed on Sf9 cells.
- Plaques were expanded and the resulting virus was screened for PCV-2 ORF-2 gene insertion by sequencing of isolated viral DNA, and immunofluorescence on Sf9 cells using anti-PCV-2 rabbit and pig sera.
- a seed of recombinant baculovirus BacPCV-2-ORF-2 was prepared called "Masterseed".
- the Masterseed and the 5 th passage of the Masterseed on Sf9 cells were tested for stable insertion of the PCV-2 ORF-2 gene by sequencing of isolated DNA and immunofluorescence on Sf 9 cells. Titrations were done to measure the amount of infectious virus in the virus preparations. Titrations were done on Sf9 cells, and were read by observing baculovirus specific CPE and/or PCV-2 ORF-2 specific immunofluorescence using polyclonal rabbit anti-PCV-2 immune serum . It was demonstrated that a plaque-purified Masterseed of recombinant ⁇ cNPV baculovirus BacPCV-2-ORF-2 was produced. This construct stably expressed the PCV-ORF-2 protein under control of the p10 promotor on Sf9 cells as judged by sequencing and immunofluorescence of the Masterseed and the 5 th passage from the Masterseed on Sf9 cells.
- the total harvest containing both cells and supernatant was subjected to sonication to the extent that at least 90% of the cells were disrupted. Thereafter the live recombinant virus in batches of sonicated harvest was inactivated with 33mM Binary Ethylenimine (BEI) at 37°C for 72 hours under continuous stirring, at a pH of 7.5. After inactivation, the BEI was neutralized by the addition of a 1.6 fold molar excess of Sodium Thiosulphate.
- BEI Binary Ethylenimine
- inactivated virus suspension After neutralization, cell debris and polyhedra were removed by low-speed centrifugation at 60Og for 10min. The resulting supernatant was named inactivated virus suspension. Harvests were checked for sterility and for completeness of inactivation. Completeness of inactivation was tested by passaging inactivated virus suspension on Sf9 cells for 2 weeks and visual inspection for the absence of baculovirus specific CPE.
- Baculovirus titres of was 8.5 log 10 TCID 50 /ml were obtained which were completely inactivated after treatment with BEI.
- PCV-2 ORF-2 Expression levels of the PCV-2 ORF-2 were determined in 5 separate experiments, and in each instance, the amount was well above the detection limit of the test, specifically ranging from 40 to 550 microgram/milliliter (ug/ml) of inactivated virus suspension.
- Example 5 Influence of the amount of PCV-2 ORF-2 on vaccine take in MDA positive young piglets.
- Vaccines of different PCV-2 ORF-2 antigen content were formulated and used to vaccinate young piglets with varying levels of maternally derived antibodies (MDA) against PCV-2. Two vaccinations were given, 3 weeks apart. The seroresponse against the antigen was measured at 5-6 weeks after the first vaccination. From these data, the influence of the antigen content on the take of the vaccine in the face of MDA was calculated.
- MDA maternally derived antibodies
- the total number of piglets protected is given by the number of piglets where the vaccine has taken in piglets with a titre smaller than 13 plus the piglets that already have a titre of 13 or higher.
- vaccine take means that the vaccination of a piglet resulted in a PCV-2 specific antibody titre at 1 week post booster vaccination that is equal or higher than the PCV-2 specific titre at primary vaccination.
- the vaccine mounted an active serum response against PCV-2 and in which case piglets can be regarded as being protected against a PCV-2 infection.
- the vaccine was unable to induce an immune response and the natural decline of maternally derived antibodies was observed which, in time, will render these animals susceptible for a PCV-2 infection.
- the antigenic mass of a vaccine directed against PCV-2 must at least contain 20 ug of antigen or more to be able to efficiently protect a herd against the consequences of a PCV-2 infection.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020087007927A KR101347503B1 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 vaccine |
CA2620727A CA2620727C (en) | 2005-09-09 | 2006-09-08 | Porcine circovirus type 2 vaccine |
US12/066,090 US20080248061A1 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 Vaccine |
BRPI0615862-5A BRPI0615862A2 (en) | 2005-09-09 | 2006-09-08 | pcv-2 vaccine, and method for manufacturing a vaccine |
AU2006289102A AU2006289102C1 (en) | 2005-09-09 | 2006-09-08 | PCV-2 vaccine |
JP2008529638A JP5106398B2 (en) | 2005-09-09 | 2006-09-08 | PCV-2 vaccine |
PL06793347T PL1926496T3 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 vaccine |
ES06793347T ES2425228T3 (en) | 2005-09-09 | 2006-09-08 | Vaccine against PCV-2 |
EP06793347.3A EP1926496B1 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 vaccine |
DK06793347.3T DK1926496T3 (en) | 2005-09-09 | 2006-09-08 | PCV-2 vaccine |
US12/636,143 US8008001B2 (en) | 2005-09-09 | 2009-12-11 | PCV-2 vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05108299.8 | 2005-09-09 | ||
EP05108299 | 2005-09-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/066,090 A-371-Of-International US20080248061A1 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 Vaccine |
US12/636,143 Division US8008001B2 (en) | 2005-09-09 | 2009-12-11 | PCV-2 vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007028823A1 true WO2007028823A1 (en) | 2007-03-15 |
Family
ID=35482131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/066161 WO2007028823A1 (en) | 2005-09-09 | 2006-09-08 | Pcv-2 vaccine |
Country Status (14)
Country | Link |
---|---|
US (2) | US20080248061A1 (en) |
EP (1) | EP1926496B1 (en) |
JP (1) | JP5106398B2 (en) |
KR (1) | KR101347503B1 (en) |
CN (1) | CN101277717A (en) |
AU (1) | AU2006289102C1 (en) |
BR (1) | BRPI0615862A2 (en) |
CA (1) | CA2620727C (en) |
DK (1) | DK1926496T3 (en) |
ES (1) | ES2425228T3 (en) |
PL (1) | PL1926496T3 (en) |
RU (1) | RU2389506C2 (en) |
UA (1) | UA95458C2 (en) |
WO (1) | WO2007028823A1 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1976558A2 (en) * | 2005-12-29 | 2008-10-08 | BOEHRINGER INGELHEIM VETMEDICA, Inc. | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US7829101B2 (en) | 2004-12-30 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
WO2011028888A2 (en) | 2009-09-02 | 2011-03-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity |
US7914992B2 (en) | 2007-01-03 | 2011-03-29 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of PRDC in pigs |
CN102006884A (en) * | 2008-04-18 | 2011-04-06 | 英特威国际有限公司 | Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus |
US7943298B2 (en) | 2007-02-13 | 2011-05-17 | Boehringer Ingelheim Vetmedica, Inc. | Prevention and treatment of sub-clinical PCVD |
US8119143B2 (en) | 2005-12-29 | 2012-02-21 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
WO2012076623A1 (en) | 2010-12-08 | 2012-06-14 | Intervet International B.V. | A method to quantify the amount of a biological substance in a sample and a kit for performing the method |
EP2481420A1 (en) | 2006-12-15 | 2012-08-01 | Boehringer Ingelheim Vetmedica, Inc. | Single dose anti-PCV2 pig vaccine |
EP2460820A3 (en) * | 2004-12-30 | 2013-01-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2564869A1 (en) * | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
CN102978232A (en) * | 2012-08-23 | 2013-03-20 | 郑州后羿制药有限公司 | Method for inducing porcine circovirus type 2 recombinant Cap protein expression through IPTG |
US8597662B2 (en) | 2008-04-18 | 2013-12-03 | Intervet International B.V. | Vaccine for protection against Lawsonia intracellularis |
WO2015082457A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
WO2015082458A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against porcine circo virus type 2 |
WO2016091998A1 (en) * | 2014-12-11 | 2016-06-16 | Intervet International B.V. | Process for ready-to-use pcv2/m.hyo combination vaccine |
CN105785037A (en) * | 2016-03-30 | 2016-07-20 | 中国农业科学院兰州兽医研究所 | Rapid-detection chromatographic test strip for antibodies in porcine circovirus-2 and preparation method |
US9505808B2 (en) | 2013-10-02 | 2016-11-29 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
US9636389B2 (en) | 2006-12-11 | 2017-05-02 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections |
US9669086B2 (en) | 2008-01-23 | 2017-06-06 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
WO2017162741A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
WO2017162727A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 and prrs virus infection comprising albumin |
WO2017162720A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A vaccine for intradermal application against pcv2 and prrs virus infection |
US9919041B2 (en) | 2004-12-30 | 2018-03-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
WO2018189290A1 (en) | 2017-04-13 | 2018-10-18 | Intervet International B.V. | Vaccines containing swine pathogens for associated non-mixed use |
WO2019025519A1 (en) | 2017-08-03 | 2019-02-07 | Intervet International B.V. | A vaccine comprising a pcv2 orf2 protein of genotype 2b |
US10201599B2 (en) | 2005-03-14 | 2019-02-12 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
WO2019022463A3 (en) * | 2017-07-24 | 2019-07-18 | (주)제이비바이오텍 | Immunogenic system and animal vaccine comprising same |
WO2019191005A1 (en) | 2018-03-26 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
WO2021048338A1 (en) | 2019-09-12 | 2021-03-18 | Intervet International B.V. | Combination vaccine for intradermal administration |
WO2021213949A1 (en) | 2020-04-20 | 2021-10-28 | Intervet International B.V. | A combination of vaccines to prophylactically treat a pig |
WO2022090357A1 (en) | 2020-10-29 | 2022-05-05 | Intervet International B.V. | Combination vaccine for protecting swine against various disorders |
RU2774926C2 (en) * | 2017-08-03 | 2022-06-24 | Интервет Интернэшнл Б.В. | VACCINE INCLUDING ORF2 PCV2 PROTEIN OF 2b GENOTYPE |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101875941A (en) * | 2010-03-09 | 2010-11-03 | 胡文锋 | Artificially modified and synthesized dORF2art gene and protein encoded by same |
KR101675185B1 (en) | 2010-07-08 | 2016-11-10 | 유나이티드 바이오메디칼 인크. | Designer peptide-based pcv2 vaccine |
CN101920012B (en) * | 2010-07-22 | 2012-12-12 | 普莱柯生物工程股份有限公司 | Method for producing porcine circovirus type II recombinant capsid protein subunit vaccine by utilizing silkworm bioreactor and products thereof |
CN102352347A (en) * | 2011-10-14 | 2012-02-15 | 浙江诺倍威生物技术有限公司 | Porcin circovirus type 2 (PCV2) recombinant baculovirus construction method and subunit vaccine preparation method thereof |
CN102517331A (en) * | 2011-12-26 | 2012-06-27 | 武汉中博生物股份有限公司 | 2 type subunit vaccine for porcine circovirus as well as preparation method and application thereof |
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
UA114504C2 (en) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | PCV, MYCOPLASMA HYOPNEUMONIA AND PRRS COMBINED VACCINE |
UA114503C2 (en) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | PCV AND MYCOPLASMA HYOPNEUMONIA COMBINED VACCINE |
BR102013001893B1 (en) | 2013-01-25 | 2022-01-25 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Recombinant porcine circovirus 2 (pcv-2) antigens for vaccine formulations, diagnostic kit and use |
WO2014182872A1 (en) | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
KR101527832B1 (en) * | 2013-05-28 | 2015-06-11 | 대한민국 | ORF2 recombinant gene of porcine circovirus type 2, transfer vector, recombinant vaculovirus, recombinant capsid protein of porcine circovirus type 2 and manufacturing method thereof |
KR102319843B1 (en) * | 2013-09-25 | 2021-10-29 | 조에티스 서비시즈 엘엘씨 | Pcv2b divergent vaccine composition and methods of use |
AR097762A1 (en) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | DRY FORMULATIONS OF VACCINES THAT ARE STABLE AT ENVIRONMENTAL TEMPERATURE |
CN104548083B (en) * | 2013-10-22 | 2019-05-07 | 洛阳赛威生物科技有限公司 | A kind of vaccine composition and its preparation method and application |
MX2020003626A (en) | 2017-10-17 | 2021-08-12 | Intervet Int Bv | Recombinant expression of pcv2b orf2 protein in insect cells. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049703A2 (en) * | 2001-12-12 | 2003-06-19 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE115862T1 (en) * | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | TOCOLE AS A VACCINE ADJUVANT. |
DK0835930T3 (en) * | 1996-10-09 | 2001-06-18 | Akzo Nobel Nv | European vaccine strains of porcine reproductive and respiratory syndrome virus. (PRRSV) |
AUPO856097A0 (en) * | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
US6517843B1 (en) * | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
FR2772047B1 (en) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
-
2006
- 2006-09-08 BR BRPI0615862-5A patent/BRPI0615862A2/en not_active Application Discontinuation
- 2006-09-08 AU AU2006289102A patent/AU2006289102C1/en active Active
- 2006-09-08 RU RU2008113763/15A patent/RU2389506C2/en active
- 2006-09-08 ES ES06793347T patent/ES2425228T3/en active Active
- 2006-09-08 KR KR1020087007927A patent/KR101347503B1/en active IP Right Grant
- 2006-09-08 UA UAA200803112A patent/UA95458C2/en unknown
- 2006-09-08 JP JP2008529638A patent/JP5106398B2/en active Active
- 2006-09-08 WO PCT/EP2006/066161 patent/WO2007028823A1/en active Application Filing
- 2006-09-08 DK DK06793347.3T patent/DK1926496T3/en active
- 2006-09-08 CA CA2620727A patent/CA2620727C/en active Active
- 2006-09-08 EP EP06793347.3A patent/EP1926496B1/en not_active Revoked
- 2006-09-08 CN CNA2006800368680A patent/CN101277717A/en active Pending
- 2006-09-08 US US12/066,090 patent/US20080248061A1/en active Granted
- 2006-09-08 PL PL06793347T patent/PL1926496T3/en unknown
-
2009
- 2009-12-11 US US12/636,143 patent/US8008001B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049703A2 (en) * | 2001-12-12 | 2003-06-19 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
Non-Patent Citations (18)
Title |
---|
BLANCHARD ET AL., VACCINE, vol. 21, 2003, pages 4565 - 4575 |
BLANCHARD P ET AL: "Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 31, 7 November 2003 (2003-11-07), pages 4565 - 4575, XP004467337, ISSN: 0264-410X * |
CHAE C: "A review of porcine circovirus 2-associated syndromes and diseases", VETERINARY JOURNAL, BAILLIERE TINDALL, LONDON,, GB, vol. 169, no. 3, May 2005 (2005-05-01), pages 326 - 336, XP004858799, ISSN: 1090-0233 * |
CHAE. C, VET. J., vol. 169, 2005, pages 326 - 336 |
CLARK ET AL., PROC. AM. ASSOC. SWINE. PRACT, 1997, pages 499 - 501 |
D.R. O'REILLY, L.K. MILLER, V.A. LUCKOW: "Baculovirus Expression vectors", 1992, W.H. FREEMAN & CO |
FENAUX ET AL., J.CLIN. MICORBIOL., vol. 38, no. 7, 2000, pages 2494 - 2503 |
HAMEL ET AL., J.VIROL., vol. 72, no. 6, 1998, pages 5262 - 5267 |
HARDING ET AL., PROC. AM. ASSOC. SWINE. PRACT, 1997, pages 503 |
KAMSTRUM ET AL., VACCINE, vol. 22, 2004, pages 1358 - 1361 |
KAMSTRUP S ET AL: "Immunisation against PCV2 structural protein by DNA vaccination of mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 11-12, 29 March 2004 (2004-03-29), pages 1358 - 1361, XP004500378, ISSN: 0264-410X * |
KIM ET AL., J.VET.SCI, vol. 3, no. 1, 2002, pages 19 - 23 |
LIU ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 21, 2001, pages 115 - 120 |
MEEHAN ET AL., J. GEN.VIROL., vol. 79, 1998, pages 2171 - 2179 |
MERIAL: "PCV-2 Diseases: From research back to the field strain", 18TH IPVS, June 2004 (2004-06-01), pages 99 - 101 |
NAYAR ET AL., CAN. VET. J., vol. 38, June 1997 (1997-06-01) |
SIEGRIST C-A: "Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 24, 28 July 2003 (2003-07-28), pages 3406 - 3412, XP004436445, ISSN: 0264-410X * |
TISCHER ET AL., NATURE, vol. 295, 1982, pages 64 - 66 |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576142B2 (en) | 2004-12-30 | 2020-03-03 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7910306B2 (en) | 2004-12-30 | 2011-03-22 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US9011872B2 (en) | 2004-12-30 | 2015-04-21 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460821A3 (en) * | 2004-12-30 | 2014-12-10 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460817A3 (en) * | 2004-12-30 | 2013-01-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460816A3 (en) * | 2004-12-30 | 2014-01-01 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460817B1 (en) | 2004-12-30 | 2017-03-29 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US7829101B2 (en) | 2004-12-30 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460820B1 (en) | 2004-12-30 | 2019-04-10 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 immunogenic compositions and methods of producing such compositions |
US9919041B2 (en) | 2004-12-30 | 2018-03-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460818A3 (en) * | 2004-12-30 | 2013-01-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US8025888B2 (en) | 2004-12-30 | 2011-09-27 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460819A3 (en) * | 2004-12-30 | 2013-01-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP2460820A3 (en) * | 2004-12-30 | 2013-01-09 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US10201599B2 (en) | 2005-03-14 | 2019-02-12 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
EP2275130A3 (en) * | 2005-12-29 | 2011-03-23 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 ORF2 immunogenic composition |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
EP1976558A2 (en) * | 2005-12-29 | 2008-10-08 | BOEHRINGER INGELHEIM VETMEDICA, Inc. | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
EP1976558A4 (en) * | 2005-12-29 | 2009-04-29 | Boehringer Ingelheim Vetmed | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
US7968285B2 (en) | 2005-12-29 | 2011-06-28 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9101561B2 (en) | 2005-12-29 | 2015-08-11 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
US10568955B2 (en) | 2005-12-29 | 2020-02-25 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9610345B2 (en) | 2005-12-29 | 2017-04-04 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US10624963B2 (en) | 2005-12-29 | 2020-04-21 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
US9669087B2 (en) | 2005-12-29 | 2017-06-06 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US7838214B2 (en) | 2005-12-29 | 2010-11-23 | Boehringer Ingelheim Vetmedical, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9987349B2 (en) | 2005-12-29 | 2018-06-05 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9925256B2 (en) | 2005-12-29 | 2018-03-27 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
AU2006338182B2 (en) * | 2005-12-29 | 2013-08-22 | Boehringer Ingelheim Animal Health USA Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9925255B2 (en) | 2005-12-29 | 2018-03-27 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
US7838213B2 (en) | 2005-12-29 | 2010-11-23 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US7829273B2 (en) | 2005-12-29 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
US9011868B2 (en) | 2005-12-29 | 2015-04-21 | Boehringer Ingelheim Vetmedica, Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
EP3127551B1 (en) | 2005-12-29 | 2020-07-29 | Boehringer Ingelheim Animal Health USA Inc. | Pcv2 immunogenic composition for lessening clinical symptoms in pigs |
US8119143B2 (en) | 2005-12-29 | 2012-02-21 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent PCV2 immunogenic compositions and methods of producing such compositions |
US9636389B2 (en) | 2006-12-11 | 2017-05-02 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and Lawsonia intracellularis infections |
US8865183B2 (en) | 2006-12-15 | 2014-10-21 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with PCV2 antigent |
EP2481420B1 (en) * | 2006-12-15 | 2019-02-20 | Boehringer Ingelheim Vetmedica, Inc. | Single dose anti-PCV2 pig vaccine |
US9517260B2 (en) | 2006-12-15 | 2016-12-13 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with PCV2 antigen |
EP2094872B2 (en) † | 2006-12-15 | 2020-02-19 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen |
EP2481420A1 (en) | 2006-12-15 | 2012-08-01 | Boehringer Ingelheim Vetmedica, Inc. | Single dose anti-PCV2 pig vaccine |
EP2094872B1 (en) * | 2006-12-15 | 2017-02-22 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen |
EP3466442A1 (en) | 2006-12-15 | 2019-04-10 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of mda seropositive pigs with pcv2 antigen |
US9522182B2 (en) | 2007-01-03 | 2016-12-20 | Boehringer Ingelheim Vetmedica, Inc. | Prophylaxis and treatment of PRDC |
US7914992B2 (en) | 2007-01-03 | 2011-03-29 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of PRDC in pigs |
US7943298B2 (en) | 2007-02-13 | 2011-05-17 | Boehringer Ingelheim Vetmedica, Inc. | Prevention and treatment of sub-clinical PCVD |
US8496940B2 (en) | 2007-02-13 | 2013-07-30 | Boehringer Ingelheim Vetmedica, Inc. | Prevention and treatment of sub-clinical PCVD |
US9555092B2 (en) | 2007-02-13 | 2017-01-31 | Boehringer Ingelheim Vetmedica, Inc. | Prevention and treatment of sub-clinical PCVD |
US9132187B2 (en) | 2007-02-13 | 2015-09-15 | Boehringer Ingelheim Vetmedica, Inc. | Prevention and treatment of sub-clinical PCVD |
US8475805B2 (en) | 2007-09-04 | 2013-07-02 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing concomitant infections in pigs with a PCV2 antigen |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US9132186B2 (en) | 2007-09-04 | 2015-09-15 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US9669086B2 (en) | 2008-01-23 | 2017-06-06 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 Mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
EP2633867B1 (en) | 2008-04-18 | 2018-03-21 | Intervet International B.V. | Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus |
US9198963B2 (en) | 2008-04-18 | 2015-12-01 | Intervet International B.V. | Vaccine for protection against Lawsonia intracellularis |
US9084768B2 (en) | 2008-04-18 | 2015-07-21 | Intervet International B.V. | Vaccine for protection against Lawsonia intracellularis, Mycoplasma hyopneumoniae and Porcine circo virus |
EP3708186A1 (en) | 2008-04-18 | 2020-09-16 | Intervet International B.V. | Vaccine for protection against lawsonia intracellularis |
CN102006884A (en) * | 2008-04-18 | 2011-04-06 | 英特威国际有限公司 | Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus |
US8597662B2 (en) | 2008-04-18 | 2013-12-03 | Intervet International B.V. | Vaccine for protection against Lawsonia intracellularis |
EP3351267A1 (en) | 2008-04-18 | 2018-07-25 | Intervet International B.V. | Vaccine for protection against lawsonia intracellularis |
EP2633867A1 (en) | 2008-04-18 | 2013-09-04 | Intervet International B.V. | Vaccine for protection against Lawsonia intracellularis, Mycoplasma hyopneumoniae and Porcine circo virus |
US9561270B2 (en) | 2009-09-02 | 2017-02-07 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity |
WO2011028888A2 (en) | 2009-09-02 | 2011-03-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity |
WO2012076623A1 (en) | 2010-12-08 | 2012-06-14 | Intervet International B.V. | A method to quantify the amount of a biological substance in a sample and a kit for performing the method |
US9550812B2 (en) | 2011-09-02 | 2017-01-24 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
EP2750704B1 (en) | 2011-09-02 | 2017-10-04 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
EP2564869A1 (en) * | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
WO2013030320A1 (en) * | 2011-09-02 | 2013-03-07 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
CN102978232A (en) * | 2012-08-23 | 2013-03-20 | 郑州后羿制药有限公司 | Method for inducing porcine circovirus type 2 recombinant Cap protein expression through IPTG |
US11858963B2 (en) | 2013-10-02 | 2024-01-02 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
US9505808B2 (en) | 2013-10-02 | 2016-11-29 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 ORF2 protein variant and virus like particles composed thereof |
EP3673916A1 (en) | 2013-12-03 | 2020-07-01 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus2 |
US10130698B2 (en) | 2013-12-03 | 2018-11-20 | Intervet Inc. | Vaccine against porcine circo virus type 2 |
US10130699B2 (en) | 2013-12-03 | 2018-11-20 | Intervet Inc. | Vaccine against Lawsonia intracellularis and porcine circovirus 2 |
WO2015082458A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against porcine circo virus type 2 |
EP3076996B1 (en) | 2013-12-03 | 2020-01-15 | Intervet International B.V. | Vaccine against porcine circo virus type 2 |
WO2015082457A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
US10568954B2 (en) | 2014-12-11 | 2020-02-25 | Intervet Inc. | Process for ready-to-use PCV/M.Hyo combination vaccine |
WO2016091998A1 (en) * | 2014-12-11 | 2016-06-16 | Intervet International B.V. | Process for ready-to-use pcv2/m.hyo combination vaccine |
US10953084B2 (en) | 2016-03-23 | 2021-03-23 | Intervet Inc. | Combination vaccine against PCV2 and PRRS virus infection comprising albumin |
WO2017162720A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A vaccine for intradermal application against pcv2 and prrs virus infection |
WO2017162727A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 and prrs virus infection comprising albumin |
US11654191B2 (en) | 2016-03-23 | 2023-05-23 | Intervet Inc. | Vaccine for intradermal application against PCV2 and PRRS virus infection |
WO2017162741A1 (en) | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
CN105785037A (en) * | 2016-03-30 | 2016-07-20 | 中国农业科学院兰州兽医研究所 | Rapid-detection chromatographic test strip for antibodies in porcine circovirus-2 and preparation method |
WO2018189290A1 (en) | 2017-04-13 | 2018-10-18 | Intervet International B.V. | Vaccines containing swine pathogens for associated non-mixed use |
US11311614B2 (en) | 2017-04-13 | 2022-04-26 | Intervet Inc. | Vaccines containing swine pathogens for associated non-mixed use |
EP4335455A2 (en) | 2017-04-13 | 2024-03-13 | Intervet International B.V. | Vaccines containing swine pathogens for associated non-mixed use |
KR20200024804A (en) * | 2017-07-24 | 2020-03-09 | (주)제이비바이오텍 | Immunogenic system and Animal vaccine thereof |
KR102182145B1 (en) * | 2017-07-24 | 2020-11-24 | (주)제이비바이오텍 | Composition for prevention and treatment of Porcine Epidemic Diarrhea Virus |
WO2019022463A3 (en) * | 2017-07-24 | 2019-07-18 | (주)제이비바이오텍 | Immunogenic system and animal vaccine comprising same |
WO2019025519A1 (en) | 2017-08-03 | 2019-02-07 | Intervet International B.V. | A vaccine comprising a pcv2 orf2 protein of genotype 2b |
US11077181B2 (en) | 2017-08-03 | 2021-08-03 | Intervet Inc. | Vaccine comprising a PCV2 ORF2 protein of genotype 2b |
RU2774926C2 (en) * | 2017-08-03 | 2022-06-24 | Интервет Интернэшнл Б.В. | VACCINE INCLUDING ORF2 PCV2 PROTEIN OF 2b GENOTYPE |
WO2019191005A1 (en) | 2018-03-26 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
WO2021048338A1 (en) | 2019-09-12 | 2021-03-18 | Intervet International B.V. | Combination vaccine for intradermal administration |
WO2021213949A1 (en) | 2020-04-20 | 2021-10-28 | Intervet International B.V. | A combination of vaccines to prophylactically treat a pig |
WO2022090357A1 (en) | 2020-10-29 | 2022-05-05 | Intervet International B.V. | Combination vaccine for protecting swine against various disorders |
Also Published As
Publication number | Publication date |
---|---|
CA2620727C (en) | 2015-06-16 |
ES2425228T3 (en) | 2013-10-14 |
AU2006289102A1 (en) | 2007-03-15 |
RU2389506C2 (en) | 2010-05-20 |
UA95458C2 (en) | 2011-08-10 |
BRPI0615862A2 (en) | 2011-05-31 |
KR101347503B1 (en) | 2014-01-02 |
EP1926496B1 (en) | 2013-06-26 |
US20080248061A1 (en) | 2008-10-09 |
AU2006289102C1 (en) | 2017-11-30 |
CA2620727A1 (en) | 2007-03-15 |
US20110064765A1 (en) | 2011-03-17 |
AU2006289102B2 (en) | 2011-12-15 |
DK1926496T3 (en) | 2013-09-30 |
EP1926496A1 (en) | 2008-06-04 |
RU2008113763A (en) | 2009-10-20 |
JP2009507811A (en) | 2009-02-26 |
PL1926496T3 (en) | 2014-02-28 |
CN101277717A (en) | 2008-10-01 |
KR20080042159A (en) | 2008-05-14 |
JP5106398B2 (en) | 2012-12-26 |
US8008001B2 (en) | 2011-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006289102C1 (en) | PCV-2 vaccine | |
US10799578B2 (en) | Vaccine against porcine parvovirus | |
US7211379B2 (en) | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 | |
US10174084B2 (en) | Fusion polypeptides and vaccines | |
JP7422795B2 (en) | Recombinant expression of PCV2b ORF2 protein in insect cells | |
US20140348874A1 (en) | Method for the reduction of pcv-2 in a herd of swine | |
JP2022527627A (en) | Type 3 porcine circovirus (PCV3) vaccine, as well as its preparation and use | |
WO2020058341A1 (en) | Intranasal vector vaccine against porcine epidemic diarrhea | |
CN114828882A (en) | Multivalent HVT vector vaccines | |
ES2344301T3 (en) | SEQUENCES, COMPOSITIONS AND VACCINES OF THE VIRUS OF THE DISEASE OF THE PEAK AND FEATHERS AND THE USE OF THE SAME IN THERAPY, DIAGNOSIS AND TESTS. | |
RU2779423C2 (en) | RECOMBINANT EXPRESSION OF PROTEIN ORF2 PCV2b IN INSECT CELLS | |
Wei et al. | Novel Approach in DNA vaccine development against porcine circovirus type 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680036868.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006793347 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2620727 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/003334 Country of ref document: MX Ref document number: 12066090 Country of ref document: US Ref document number: 2008529638 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006289102 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087007927 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008113763 Country of ref document: RU Ref document number: a200803112 Country of ref document: UA Ref document number: 1200800862 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2006289102 Country of ref document: AU Date of ref document: 20060908 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006289102 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006793347 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0615862 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080307 |